Blog

Search results : ceo overconfidence

Stock market misvaluation and corporate investment payout

John Fourier

2022-11-15 10:30:00 Tuesday ET

Stock market misvaluation and corporate investment payout The behavioral catering theory suggests that stock market misvaluation can have a first-order impact on major corporate investment and payout decisions wh...
+See More
CEO overconfidence and corporate performance

Laura Hermes

2022-11-05 11:32:00 Saturday ET

CEO overconfidence and corporate performance Malmendier and Tate (JFE 2008, JF 2005) argue that overconfident CEOs are more likely to initiate mergers and acquisitions that erode shareholder value. The odds of ini...
+See More
Corporate investment insights from mergers and acquisitions

Joseph Corr

2022-10-25 11:31:00 Tuesday ET

Corporate investment insights from mergers and acquisitions Relative market misvaluation between the bidder and target firms drives most waves of mergers and acquisitions (Loughran and Vijh, JF 1997; Shleifer and ...
+See More
Corporate ownership governance theory and practice

Monica McNeil

2022-04-25 10:34:00 Monday ET

Corporate ownership governance theory and practice  The genesis of modern corporate governance and ownership studies traces back to the seminal work of Berle and Means (1932). The Berle-Means theory serves as...
+See More
Corporate investment management

Charlene Vos

2022-04-15 10:32:00 Friday ET

Corporate investment management  This review of corporate investment literature focuses on some recent empirical studies of M&A, capital investment, and R&D innovation. This focus spans the empirical ...
+See More
1


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Donald Trump defies the odds to become the new U.S. president.

John Fourier

2016-11-08 00:00:00 Tuesday ET

Donald Trump defies the odds to become the new U.S. president.

Donald Trump defies the odds to become the new U.S. president. He wants to make America great again. He seeks to repeal Obamacare. He has zero tole

+See More

Central banks learn to weigh the monetary policy trade-offs between output and inflation expectations and macro-financial stress conditions.

Becky Berkman

2026-01-31 10:31:00 Saturday ET

Central banks learn to weigh the monetary policy trade-offs between output and inflation expectations and macro-financial stress conditions.

  In recent years, several central banks conduct, assess, and discuss the core lessons, rules, and challenges from their monetary policy framework r

+See More

Buffett discusses Berkshire's cash ambition, its reinsurance business, and his succession plan.

Becky Berkman

2018-02-23 09:35:00 Friday ET

Buffett discusses Berkshire's cash ambition, its reinsurance business, and his succession plan.

Warren Buffett releases his annual letter to Berkshire Hathaway shareholders as of February 2018. Buffett discusses Berkshire's core cash ambition, its

+See More

Smart firms and customers connect the continuous flow of lean production to the lean consumption of cost-effective minimum viable products.

Olivia London

2020-07-26 15:29:00 Sunday ET

Smart firms and customers connect the continuous flow of lean production to the lean consumption of cost-effective minimum viable products.

Firms and customers create value and wealth together by joining the continual flow of small batches of lean production to the lean consumption of cost-effec

+See More

The great reversal of antitrust merger review in America

Monica McNeil

2023-10-07 10:24:00 Saturday ET

The great reversal of antitrust merger review in America

Thomas Philippon draws attention to greater antitrust scrutiny in light of the rise of market power and its economic ripple effects. Thomas Philippon (20

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More